中药治疗特发性肺纤维化系统评价/Meta分析的再评价＊

目的 对中药治疗特发性肺纤维化系统评价/Meta分析进行再评价研究,以期为临床医师及研究者提供更科学的决策支持。方法 检索中药治疗特发性肺纤维化系统评价/Meta分析的文献,筛选文献后提取资料,采用AMSTAR2（A Measurement Tool To Assess Systematic Reviews 2）量表和GRADE（Grade of Recommendation,Assessment,Development,and Evaluation）系统工具进行评估。结果 共纳入14篇文献,106次结局指标;AMSTAR2量表结果示3篇属于低质量,11篇属于极低质量;GRADE分级显示,10次结局指标证据质量等级中等,83次等级低,13次等级极低。结论 中药治疗特发性肺纤维化系统评价/Meta分析的方法学质量为低、极低,结局指标的证据质量等级多为低,高质量、证据强度高级别的系统评价亟需开展,从而作为高级别证据来指导临床。

Re-evaluation of Systematic Reviews/Meta-Analysis of Chinese Medicinals for Idiopathic Pulmonary Fibrosis

Objective To reevaluate the systematic reviews/meta-analysis of Chinese medicinals for idiopathic pulmonary fibrosis to provide more scientific decision support for clinicians and researchers.Methods The systematic reviews/meta-analysis of Chinese herbal medicine for idiopathic pulmonary fibrosis were searched, and the data were extracted after literature screening, using the AMSTAR2 (A Measurement Tool To Assess Systematic Reviews 2) scale and the GRADE (Grade of (A Measurement Tool To Assess Systematic Reviews 2) scale and the GRADE of Recommendation, Assessment, Development, and Evaluation (GRADE) systematic tool were used to evaluate.Results A total of 14 publications with 107 outcome indicators were included; the results of AMSTAR2 scale showed that 3 were of low quality and 11 were of very low quality; GRADE showed that 10 outcome indicators were of moderate quality of evidence, 83 were of low grade, and 13 were of very low grade.Conclusion The methodological quality of systematic evaluation/Meta-analysis of Chinese medicine for idiopathic pulmonary fibrosis was low and very low, and the evidence quality grade of outcome indicators was mostly low; systematic evaluation with high quality and high evidence strength is urgently needed so that it can be used as high-level evidence to guide clinical practice.